Recent Finacing
Recent Raise
Alladapt Immunotherapeutics is a clinical-stage biopharmaceutical developing ADP101, a broad‑spectrum oral immunotherapy covering nine food-allergen groups, conducting randomized Phase 1/2 and open-label extension trials and building a manufacturing facility.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
